{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:38:43Z","timestamp":1791506323906,"version":"4.3.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Guillain-Barr\u00e9 syndrome (GBS) is an acute autoimmune neuropathy characterized by progressive muscle weakness, often caused by immunoglobulin G (IgG) autoantibodies. There are several subtypes of GBS, of which acute motor axonal neuropathy (AMAN) is one of the most severe subtypes associated with axonal damage. It is well known that the current clinical standard of treatment is intravenous immunoglobulin (IVIg) and plasma exchange (PLEX), but some patients often show limited response or experience persistent disability. Efgartigimod, an Fc fragment of human IgG antibody, provides a way to target and reduce pathogenic IgG antibodies as a natural ligand Fc receptor (FcRn). The purpose of this study was to observe the therapeutic effect of efgartigimod on axonal GBS, which is expected to be a potential therapeutic method for GBS and AMAN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We present a case of a 58-year-old man diagnosed with AMAN, presenting with ascending symmetrical limb weakness, flaccid paralysis, and multiple cranial nerve palsies. Electromyography confirmed the axonal subtype of GBS. Despite receiving IVIg and PLEX, the patient showed suboptimal recovery. Subsequently, he was treated with efgartigimod at a dose of 10\u2009mg\/kg weekly for 4 weeks, demonstrating significant improvement in both clinical symptoms and electromyographic findings, with good tolerability.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Result:<\/jats:title>\n            <jats:p>This case highlights the potential efficacy and safety of a 4-dose efgart-igimod regimen in AMAN, particularly for patients with inadequate response to conventional therapies. By targeting FcRn and promoting IgG degradation, efgartigimod offers a novel mechanism to modulate the aberrant immune response underlying AMAN.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Efgartigimod at a dose of 10\u2009mg\/kg weekly for 4 weeks demonstrated promising results in this case of AMAN. While further research is warranted, our findings suggest that efgartigimod may represent a valuable addition to the therapeutic armamentarium for AMAN and potentially other autoimmune neurological conditions. Well-designed clinical trials are crucial to confirm these findings and establish optimal treatment protocols for efgartigimod in AMAN.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000040700","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T21:00:10Z","timestamp":1733778010000},"page":"e40700","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Resolution of acute motor axonal neuropathy in a patient after treatment with efgartigimod: A case report"],"prefix":"10.1097","volume":"103","author":[{"given":"Jinli","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Neurology, Yiwu Hospital Affiliated to Wenzhou Medical University, Yiwu Central Hospital, Yiwu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weifei","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yiwu Hospital Affiliated to Wenzhou Medical University, Yiwu Central Hospital, Yiwu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yiwu Hospital Affiliated to Wenzhou Medical University, Yiwu Central Hospital, Yiwu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6592-1704","authenticated-orcid":false,"given":"Chanhong","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yiwu Hospital Affiliated to Wenzhou Medical University, Yiwu Central Hospital, Yiwu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital, Zhejiang University, Medical School, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1093\/brain\/109.6.1115","article-title":"An acute axonal form of Gguillain-Barr\u00e9e polyneuropathy.","volume":"109 (Pt 6)","author":"Feasby","year":"1986","journal-title":"Brain"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"11404","DOI":"10.1073\/pnas.0402391101","article-title":"Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome.","volume":"101","author":"Yuki","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/ana.410380214","article-title":"Acute axonal Guillain-Barr\u00e9 syndrome with IgG antibodies against motor axons following parenteral gangliosides.","volume":"38","author":"Illa","year":"1995","journal-title":"Ann Neurol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1007\/s00415-015-7806-4","article-title":"Ambiguous value of anti-ganglioside IgM autoantibodies in GuillainBarr\u00e9 syndrome and its variants.","volume":"262","author":"Koga","year":"2015","journal-title":"J Neurol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age.","volume":"7","author":"Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1007\/s00415-024-12321-4","article-title":"Efgartigimod in the treatment of Guillain-Barr\u00e9 syndrome.","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1002\/ana.410270707","article-title":"Assessment of current diagnostic criteria for Guillain- Barr\u00e9 syndrome.","volume":"27","author":"Asbury","year":"1990","journal-title":"Ann Neurol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"10","DOI":"10.17843\/rpmesp.2019.361.3729","article-title":"Epidemiolog\u00eda del s\u00edndrome de Guillain-Barr\u00e9 en el Per\u00fa.","volume":"36","author":"Munayco","year":"2019","journal-title":"Rev Peru Med Exp Salud Publica"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrneurol.2016.172","article-title":"Guillain-Barr\u00e9 syndrome: a century of progress.","volume":"12","author":"Goodfellow","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome.","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of GuillainBarr\u00e9 syndrome in ten steps.","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1080\/14712598.2018.1468885","article-title":"The immunotherapy of Guillain-Barr\u00e9 syndrome.","volume":"18","author":"Restrepo-Jim\u00e9nez","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"R13-20250504","first-page":"CD001798","article-title":"Plasma exchange for Guillain-Barr\u00e9 syndrome.","volume":"2","author":"Chevret","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11940-020-0616-8","article-title":"Newer immunotherapies for the treatment of acute neuromuscular disease in the critical care unit.","volume":"22","author":"Patel","year":"2020","journal-title":"Curr Treat Options Neurol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/CND.0000000000000235","article-title":"Immunoglobulin treatment in neuromuscular medicine.","volume":"20","author":"Burakgazi","year":"2019","journal-title":"J Clin Neuromuscul Dis"},{"key":"R16-20250504","first-page":"713","article-title":"Complications in patients treated with plasmapheresis in the intensive care unit.","volume":"45","author":"Szczeklik","year":"2013","journal-title":"Anaesthesiol Intensiv Ther"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.","volume":"20","author":"Walgaard","year":"2021","journal-title":"Lancet Neurol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0065-2776(08)60254-0","article-title":"Biological activities of immunoglobulins of different classes and subelasses.","volume":"19","author":"Spiegelberg","year":"1974","journal-title":"Adv Immunol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s10875-010-9468-4","article-title":"Neonatal Fc receptor: from immunity to therapeutics.","volume":"30","author":"Kuo","year":"2010","journal-title":"J Clin Immunol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1074\/mcp.M116.064675","article-title":"A two-pronged binding mechanism of IgG to the neonatal Fc receptor controls complex stability and IgG serum half-life.","volume":"16","author":"Jensen","year":"2017","journal-title":"Mol Cell Proteomics"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/eji.1830260327","article-title":"Abnormally short serum half-lives of IgG in beta 2-microglobulindeficient mice.","volume":"26","author":"Ghetie","year":"1996","journal-title":"Eur J Immunol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"5512","DOI":"10.1073\/pnas.93.11.5512","article-title":"The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor.","volume":"93","author":"Junghans","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/intimm\/dxg018","article-title":"Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans.","volume":"15","author":"Ward","year":"2003","journal-title":"Int Immunol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"20210226","DOI":"10.1177\/1756286421997381","article-title":"The importance of FcRn in neuroimmunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efciency to specifc FcRn inhibitors.","volume":"14","author":"Dalakas","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:07:16Z","timestamp":1746320836000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000040700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":25,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000040700","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]}}}